Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Acq. announced
Appointed director
Notes underwriting agrmnt
Kura Oncology, Inc. (KURA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Kura Oncology Reports Second Quarter 2023 Financial Results – Enrollment in registration-directed trial of ziftomenib in NPM1-mutant AML continues to outperform projections – – First patients dosed in combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – Late-breaking clinical data for ziftomenib in NPM1-mutant AML presented at EHA – – Continued evidence of clinical activity observed in trial of tipifarnib plus alpelisib in PIK3CA-dependent HNSCC – – First-in-human study of next-generation FTI KO-2806 to begin in second half of 2023 – – $477 million in cash, equivalents and investments provide runway to mid-2026 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, Aug. 3, 2023– Kura Oncology, Inc. , a clinical-stage biopharmaceutical c..."
06/12/2023 8-K Investor presentation
Docs: "Presentation Materials of Kura Oncology, Inc"
06/02/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "KURA ONCOLOGY, INC. OPTION AGREEMENT Pursuant to your Stock Option Grant Notice and this Option Agreement, Kura Oncology, Inc. has granted you an option under its Amended and Restated 2014 Equity Incentive Plan to purchase the number of shares of the Company’s Common Stock indicated in your Grant Notice at the exercise price indicated in your Grant Notice. The option is granted to you effective as of the date of grant set forth in the Grant Notice . If there is any conflict between the terms in this Option Agreement and the Plan, the terms of the Plan will control. Capitalized terms not explicitly defined in this Option Agreement or in the Grant Notice but defined in the Plan will have the same definitions as in the Plan. The details of your option, in addition to those set forth in the Gr..."
04/19/2023 8-K Quarterly results
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
02/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results – Phase 1 data for ziftomenib highlighted by 30% CR rate among 20 patients with NPM1-mutant AML treated at recommended Phase 2 dose – – Multiple patients dosed in registration-directed trial of ziftomenib in NPM1-mutant AML – – First combination study of ziftomenib in NPM1-mutant and KMT2A-rearranged AML on track to initiate in first half of 2023 – – IND for KO-2806, a next-generation farnesyl transferase inhibitor, cleared by FDA – – $25 million strategic equity investment from Bristol Myers Squibb – – $438 million in cash, equivalents and investments provide runway into fourth quarter of 2025 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, Feb. 23, 2023 – Kura Oncology, Inc. , ..."
01/13/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
01/09/2023 8-K Investor presentation
Docs: "Presentation Materials of Kura Oncology, Inc",
"Presentation Materials of Kura Oncology, Inc"
12/12/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
11/03/2022 8-K Quarterly results
09/29/2022 8-K Quarterly results
08/03/2022 8-K Quarterly results
Docs: "Kura Oncology Reports Second Quarter 2022 Financial Results – Recommended Phase 2 dose for ziftomenib identified, pending FDA review – – Additional 18 patients enrolled in KOMET-001 trial of ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – Preliminary activity observed in KURRENT-HN trial of tipifarnib plus alpelisib in PIK3CA-dependent HNSCC, first patient dosed in HRAS overexpression cohort – – $450 million in cash, cash equivalents and investments provide runway through 2024 – – Management to host webcast and conference call today at 4:30 p.m. ET – SAN DIEGO, August 3, 2022 – Kura Oncology, Inc. , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported second quarter 2022 financial results and..."
06/23/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
02/01/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
01/20/2022 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
11/24/2021 8-K Other Events  Interactive Data
11/04/2021 8-K Quarterly results
Docs: "Kura Oncology Reports Third Quarter 2021 Financial Results – Continued enrollment in Phase 1b study of menin inhibitor KO-539 in NPM1-mutant and KMT2A-rearranged relapsed/refractory AML –"
08/05/2021 8-K Quarterly results
07/29/2021 8-K Quarterly results
06/25/2021 8-K Quarterly results
06/04/2021 8-K Quarterly results
05/24/2021 8-K Quarterly results
05/17/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
02/24/2021 8-K Quarterly results
01/08/2021 8-K Quarterly results
12/09/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement, by and among Kura Oncology, Inc., SVB Leerink LLC, Credit Suisse Securities (USA) LLC, Barclays Capital Inc., and Stifel, Nicolaus & Company, Incorporated, as representatives of the several underwriters named therein",
"Opinion of Cooley LLP",
"Kura Oncology Announces Commencement of Public Offering of Common Stock SAN DIEGO, December 7, 2020 - Kura Oncology, Inc. , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $200,000,000 of shares of its common stock. In connection with the offering, Kura expects to grant the underwriters a 30-day option to purchase up to an additional $30,000,000 of the shares of common stock offered in the public offering. All of the shares in the proposed offering will be offered by Kura. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or term...",
"Kura Oncology Announces Pricing of $300 Million Public Offering of Common Stock SAN DIEGO, Dec. 8, 2020 - Kura Oncology, Inc. , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 8,110,000 shares of its common stock at a price to the public of $37.00 per share. The gross proceeds to Kura from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Kura, are expected to be approximately $300 million. In addition, Kura has granted the underwriters a 30-day option to purchase up to an additional 1,216,500 shares of common stock. The offering is expected to close on or about December 11, 2020, subje..."
12/07/2020 8-K Investor presentation
Docs: "Presentation Materials of Kura Oncology, Inc"
11/05/2020 8-K Quarterly results
Docs: "Preliminary data for KO-539 accepted for oral presentation at ASH – An abstract reporting preliminary data from KOMET-001, a first-in-human study of the Company’s oral, potent and selective menin inhibitor, KO-539, has been accepted for oral presentation at ASH. The abstract, posted on the ASH website on November 4, 2020, highlighted encouraging safety and tolerability, as well as evidence of anti-leukemic activity as of the data cutoff of August 10, 2020. Kura plans to present a more mature dataset, including data from approximately 10 patients, in the oral presentation at ASH on December 5, 2020, followed by a virtual investor event featuring two of the trial’s investigators. • KO-539 approaching recommended Phase 2 dose, expansion cohorts – Kura remains focused on its goal of rea..."
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy